Resection of retroperitoneal soft-tissue sarcoma involving the abdominal aorta

2020 ◽  
Vol 13 (11) ◽  
pp. e237107
Author(s):  
Sergio Damián Quildrian ◽  
Walter Sebastián Nardi ◽  
Michel David
Keyword(s):  
Soft Tissue ◽  
Abdominal Aorta ◽  
Vascular Graft ◽  
Soft Tissue Sarcomas ◽  
Vascular Reconstruction ◽  
Vascular Involvement ◽  
Curative Intent ◽  
Complete Surgical Resection ◽  
Primary Retroperitoneal ◽  
Infrarenal Abdominal Aorta

Complete surgical resection of soft-tissue sarcomas (STSs) frequently requires complex multivisceral resections, which is the most important factor related to overall survival and local recurrence. Major vascular involvement is not rare in patients with primary retroperitoneal STSs. We present a 54-year-old woman with a retroperitoneal STS encasing the infrarenal abdominal aorta. The patient underwent complete oncological resection with vascular reconstruction using a bi-iliac vascular graft. Major blood vessel involvement is not a contraindication for STS surgery with a curative intent.

A randomized phase II study of durvalumab and tremelimumab compared to doxorubicin in patients with advanced or metastatic soft tissue sarcoma (MEDISARC, AIO-STS 0415).

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. TPS11075-TPS11075
Author(s):  
Viktor Grünwald ◽  
Sebastian Bauer ◽  
Barbara Hermes ◽  
Philipp Ivanyi ◽  
Lars H Lindner ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Overall Survival ◽  
Soft Tissue ◽  
Phase Ii ◽  
Checkpoint Inhibitors ◽  
Performance Status ◽  
Soft Tissue Sarcomas ◽  
Predictive Biomarkers ◽  
Ecog Performance Status ◽  
Curative Intent

TPS11075 Background: Soft tissue sarcomas (STS) are rare tumors and exhibit substantial histological diversity. Efficacious targeted 1st line treatment for advanced or metastatic STS is not available, and the standard therapy has been anthracycline-based for decades. This strategy shows poor efficacy, as demonstrated by a median Overall Survival (OS) of 12-20 months. Several STS subtypes, however, have been shown to express PD-L1, and immune checkpoint inhibitors (ICI) have demonstrated principle anti-tumor activity in pretreated STS. Our ongoing clinical trial tests the activity and safety of ICI combination therapy in the first-line setting. We hypothesize that the dual checkpoint blockade with Durvalumab (PD-L1) and Tremelimumab (CTLA-4) improves overall survival in STS when compared to the standard of care doxorubicin. Methods: MEDISARC is a multi-center phase II trial that is enrolling adult treatment-naïve patients with histologically confirmed STS of intermediate or high grade (FNCLCC grade 2 or 3) not amenable to surgery with curative intent and ECOG performance status 0-2. Chemosensitive histologic STS are eligible. 100 patients will be randomized 1:1, stratified by ECOG status (0 vs. 1/2). Patients in the experimental arm are treated with fixed doses of durvalumab (1.5 g Q4W) and tremelimumab (75 mg Q4W for 3 cycles, then Q12W) until Progressive Disease (PD) or for a maximum of 12 months. Doxorubicin treatment in the standard arm is at 75 mg/m2 Q3W and limited to 6 cycles. OS is the primary endpoint. Secondary endpoints include 2-year OS rate, PFS, ORR according to conventional and modified RECIST 1.1, safety and tolerability and health-related quality of life (EORTC QLQ-C30). OS analysis may be performed when the required number of events (E=70) has been observed. All randomized and treated subjects will be included in the efficacy and safety analysis. The accompanying translational research aims to identify prognostic and predictive biomarkers in blood and tumor tissue. Enrollment of patients started in April 2018 and is ongoing. As of February 2019, 32 patients have been enrolled. The study is sponsored by AIO-Studien-gGmbH, Berlin, Germany. Clinical trial information: 2016-004750-15.

Primary retroperitoneal soft-tissue sarcomas

1984 ◽  
Vol 25 (1) ◽  
pp. 8-11 ◽  
Author(s):  
Yehuda G. Adam ◽  
Jan Oland ◽  
Ariel Halevy ◽  
Renate Reif
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Primary Retroperitoneal

scholarly journals Surgical outcomes of vascular reconstruction in soft tissue sarcomas of the lower extremities

2015 ◽  
Vol 62 (1) ◽  
pp. 143-149 ◽  
Author(s):  
Kenji Nishinari ◽  
Mariana Krutman ◽  
Samuel Aguiar Junior ◽  
Bruno Soriano Pignataro ◽  
Guilherme Yazbek ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Surgical Outcomes ◽  
Soft Tissue Sarcomas ◽  
Lower Extremities ◽  
Vascular Reconstruction

Primary Retroperitoneal Soft-Tissue Sarcomas

1984 ◽  
Vol 132 (2) ◽  
pp. 417-417
Author(s):  
Y.G. Adam ◽  
J. Oland ◽  
A. Halevy ◽  
R. Reif
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Primary Retroperitoneal

Vascular Reconstruction in the Resection of Soft Tissue Sarcomas

2000 ◽  
Vol Volume 13 (Number 2) ◽  
pp. 0067-0084
Author(s):  
Christopher M. Ceraldi ◽  
To-Nao Wang ◽  
Richard J. O'Donnell ◽  
P. T. Mcdonald ◽  
Steven G. Granelli
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Vascular Reconstruction

scholarly journals Blood Transfusion Requirements for Patients With Sarcomas Undergoing Combined Radio- and Chemotherapy

Sarcoma ◽  
2005 ◽  
Vol 9 (3-4) ◽  
pp. 119-125
Author(s):  
Karen R. Sherbourne ◽  
Helena M. Earl ◽  
Lynne Whitehead ◽  
Sarah J. Jefferies ◽  
Neil G. Burnet
Keyword(s):  
Soft Tissue ◽  
Blood Transfusion ◽  
Soft Tissue Sarcomas ◽  
Intensive Treatment ◽  
Intensive Chemotherapy ◽  
Curative Intent ◽  
Transfusion Requirements ◽  
Patient Groups

Patients with bony and soft tissue sarcomas may require intensive treatment with chemotherapy and radiotherapy, which often leads to a fall in haemoglobin levels, requiring blood transfusion. There may be advantages in predicting which patients will require transfusion, partly because anaemia and hypoxia may worsen the response of tumours to chemotherapy and radiotherapy. Between 1997 and 2003, a total of 26 patients who received intensive treatment with curative intent were identified. Transfusions were given to maintain the haemoglobin at 10g/dl or above during chemotherapy, and at 12 g/dl or above during radiotherapy. Eighteen (69%) required a transfusion, the majority as a result of both the chemotherapy and RT criteria. There were 78 transfusion episodes, and 181 units of blood given. In the 18 patients who required transfusion, the average number of units was 10.1, but seven patients required more blood than this. The most significant factor influencing blood transfusion was choice of intensive chemotherapy. Intensive chemotherapy and presenting Hb less than 11.6 g/dl identified 13 out of 18 patients who needed transfusion. Adding a drop in haemoglobin of greater than 1.7 g/dl after one cycle of chemotherapy identified 16 out of 18 patients who required transfusion. The seven patients who had heavy transfusion requirements were identified by age 32 or less, intensive chemotherapy and a presenting Hb of 12 g/dl or less. Erythropoietin might be a useful alternative to transfusion in selected patient groups, especially those with heavy transfusion requirements.

scholarly journals Vascular Reconstruction for Limb Salvage in Soft Tissue Sarcomas of Thigh.

1999 ◽  
Vol 48 (1) ◽  
pp. 296-299
Author(s):  
Kimiaki Nishida ◽  
Kensuke Yonemura ◽  
Teiji Kato ◽  
Toshitake Yakushiji ◽  
Katsumasa Takagi
Keyword(s):  
Soft Tissue ◽  
Limb Salvage ◽  
Soft Tissue Sarcomas ◽  
Vascular Reconstruction

Limb Preservation Using Vascular Reconstruction in Patients with Large Extremity Soft Tissue Sarcomas: Results of Multi-Modality Therapy

2020 ◽  
Vol 82 (6) ◽  
pp. 1088-1093
Author(s):  
Sunil Kumar ◽  
N. M. L. Manjunath ◽  
S. Manoj Gowda ◽  
Naveen Kumar ◽  
Sachidanand Bharati ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Soft Tissue Sarcomas ◽  
Vascular Reconstruction ◽  
Limb Preservation
Sign in / Sign up

Export Citation Format

Share Document